Clin2
NCT07523048Possibly a fitRecruiting

Dextromethorphan-Bupropion for Moderate-to-Severe Depression

Major Depressive Disorder (MDD)

Part of Mental health clinical trials.

This study tests a combination medication (dextromethorphan plus bupropion) to see how it affects brain activity in people with moderate-to-severe depression. Researchers use brain imaging (fMRI) to understand how the drug works and whether it may help relieve depression symptoms.

Summary written for real people, not researchers, by Clin2.

Phase
Phase 2
Enrollment
30 people
Ages
18 years to 65 years
Study type
Interventional

Who can take part

  • Age 18–65 and able to provide informed consent
  • Currently experiencing moderate-to-severe depression (confirmed by clinical assessment)
  • Tried fewer than 5 antidepressant medications in the past without success
  • Able to undergo brain imaging (fMRI) scans safely, with no metal implants or pacemakers
  • Reliable internet access and ability to read and speak English
  • Not pregnant, breastfeeding, or planning pregnancy in the next 6 months

View the official record on ClinicalTrials.gov

Quick eligibility check

Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.

Similar studies

Other trials that look related to this one.

NCT06958692Recruiting· Phase 3
Testing a new antidepressant combination for depression

This study tests a new combination of two medications (dextromethorphan and bupropion) as a treatment for major depressive disorder. It may be an option if you have not already tried many antidepressants that didn't work.

Beijing, Beijing Municipality
NCT06675851Recruiting· Phase 4
Dopamine changes in the brains of depressed and healthy people

This study uses brain scans to look at dopamine — a chemical messenger related to reward and mood — in people with depression and healthy volunteers. Researchers want to understand how dopamine changes in depression, which may lead to better treatments.

Vienna
NCT06827431Not yet recruiting· Phase 3
Testing ammoxetine for depression

This trial tests an investigational medication called ammoxetine for people with moderate to severe depression. It aims to see if the drug can reduce depressive symptoms and is for those who haven't had success with certain other antidepressants.

NCT07043738Not yet recruiting
Comparing two types of brain stimulation for depression

This trial tests if using brain imaging to guide the placement of transcranial magnetic stimulation (TMS) works better than the usual scalp-based targeting method for adults with treatment-resistant depression.

NCT07562191Recruiting· Phase 2
Inhaled DMT for major depression

This trial tests if inhaling DMT can help treat moderate to severe major depression. You may qualify if your depression has lasted at least two weeks and you have not changed medications recently.

Fortaleza, Ceará
NCT06793397Recruiting· Phase 3
Study of an experimental psychedelic-like drug for depression (CYB003)

This study tests an investigational medication (CYB003) for people with major depression whose current antidepressant isn't working well enough. It looks at whether this treatment can help improve depression symptoms.

Birmingham, Alabama

Hear when a new Major Depressive Disorder (MDD) trial opens

We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.